Pathogenesis and Clinical Physiology of Hypertension

Cardiology Clinics

Volumn 28, Issue 4, 2010, Pages 545-559

  Singh, Mukesh ^a   Mensah, George A ^b   Bakris, George ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b PEPSICO INC   (United States)

Author keywords

Clinical physiology; Hypertension; Pathogenesis; Pathophysiologic mechanisms

Indexed keywords

ADRENERGIC RECEPTOR; ANGIOTENSIN II; ENDOTHELIN; NITRIC OXIDE;

ADRENERGIC SYSTEM; BLOOD PRESSURE REGULATION; CENTRAL NERVOUS SYSTEM; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; GENE FUNCTION; GENE INTERACTION; GENE MUTATION; GENETIC POLYMORPHISM; HEREDITY; HUMAN; HYPERINSULINEMIA; HYPERTENSION; HYPERTROPHY; INSULIN RESISTANCE; KIDNEY FAILURE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASCULAR RESISTANCE;

ANIMALS; ARTERIOSCLEROSIS; BLOOD PRESSURE; BRAIN STEM; ENDOTHELIUM, VASCULAR; FEEDBACK, PHYSIOLOGICAL; GENOTYPE; HEMODYNAMICS; HORMONES; HUMANS; HYPERTENSION; INSULIN RESISTANCE; KIDNEY; LIFE STYLE; PARASYMPATHETIC NERVOUS SYSTEM; PRESSORECEPTORS; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SOCIAL ENVIRONMENT; SYMPATHETIC NERVOUS SYSTEM; VAGUS NERVE; VASCULAR RESISTANCE;

EID: 77957731087     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2010.07.001     Document Type: Review

References (102)

1. Guyton A.C. Dominant role of the kidneys and accessory role of whole-body autoregulation in the pathogenesis of hypertension. Am J Hypertens 1989, 2:575-585.
2. Guyton A.C., Coleman T.G., Cowley A.V., et al. Arterial pressure regulation: overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med 1972, 52:584-594.
3. Hall J.E., Coleman T.G., Guy ton A.C. The renin-angiotensin system. Normal physiology and changes in older hypertensives. J Am Geriatr Soc 1989, 37:801-813.
4. Guyton A.C. Abnormal renal function and autoregulation in essential hypertension. Hypertension 1991, 18:11149-11153.
5. Izzo J.L., Taylor A.A. The sympathetic nervous system and baroreflexes in hypertension and hypotension. Curr Hypertens Rep 1999, 1:254-263.
6. Sobel B.J., Bakris G.L. Hypertension: a clinician's guide to diagnosis and treatment 1999, Hanley & Belfus, Philadelphia.
7. Mohrman D.E., Heller L.J. Regulation of arterial pressure. Cardiovascular physiology 2006, McGraw Hill, New York, p. 161-83. Chapter 9. 6th edition. D.E. Mohrman, L.J. Heller (Eds.).
8. Krakoff L.R., Dziedzic S., Mann S.J., et al. Plasma epinephrine concentration in healthy men: correlation with systolic pressure and rate-pressure product. J Am Coll Cardiol 1985, 5:352-356.
9. Itoh S., Carrelero O.A. Role of the macula densa in renin release. Hypertension 1985, 7:149-154.
10. Kopp U.C., DiBona G.F. Neural regulation of renin secretion. Semin Nephrol 1993, 13:543-551.
11. Lorenz J.N., Weihprecht H., Schnermann J., et al. Renin release from isolated juxtaglomerular apparatus depends on macula densa chloride transport. Am J Physiol 1991, 260:F486-F493.
12. Guyton A.C. Long-term arterial pressure control: an analysis from animal experiments and computer and graphic models. Am J Physiol 1990, 259:R865-R877.
13. Lundie M.J., Friberg P., Kline R.L., et al. Long-term inhibition of the renin-angiotensin system in genetic hypertension: analysis of the impact on blood pressure and cardiovascular structural changes. J Hypertens 1997, 15:339-348.
14. Guyton A.C. The surprising kidney-fluid mechanism for pressure control-its infinite gain!. Hypertension 1990, 16:725-730.
15. Guyton A.C., Manning R.D., Hall J.E., et al. The pathogenic role of the kidney. J Cardiovasc Pharmacol 1984, 6(Suppl l):S151-S161.
16. Hall J.E., Guyton A.C., Coleman T.G., et al. Regulation of arterial pressure: role of pressure natriuresis and diuresis. Fed Proc 1986, 45:2897-2903.
17. Triel B., Weder A.B. Genes for essential hypertension: hype, help, or hope?. J Clin Hypertens (Greenwich) 2000, 2:187-193.
18. Slocks P. A biometric investigation of twins and their brothers and sisters. Ann Eugen 1930, 4:49-62.
19. Lifton R.P., Gharavi A.G., Geller D.S. Molecular mechanisms of human hypertension. Cell 2001, 104:545-556.
20. Luft F.C. Geneticism of essential hypertension. Hypertension 2004, 43:1155-1159.
21. Barlassina C., Lanzani C., Manunta P., et al. Genetics of essential hypertension: from families to genes. J Am Soc Nephrol 2002, 13(Suppl 3):S155-S164.
22. Luft F.C. Molecular genetics of human hypertension. J Hypertens 1998, 16:1871-1878.
23. Williams R.R., Hunt S.C., Hopkins P.N., et al. Tabulations and expectations regarding the genetics of human hypertension. Kidney Int 1994, 45(Suppl 44):S57-S64.
24. Harrap S.B. Hypertension: genes versus environment. Lancet 1994, 344:169-171.
25. Pausova Z., Tremblay J., Harriet P. Gene-environment interactions in hypertension. Curr Hypertens Rep 1999, 1:42-50.
26. Sims J., Hewitt J.K., Kelly K.A., et al. Familial and individual influences on blood pressure. Acta Genet Med Gemellol (Roma) 1986, 35:7-21.
27. Sing C.F., Boerwinkle E., Turner S.T. Genetics of primary hypertension. Clin Exp Hypertens A 1986, 8:623-651.
28. Stamler J., Rose G., Elliott P., et al. Findings of the International Cooperative INTERSALT Study. Hypertension 1991, 17(Suppl):9-15.
29. Luft F.C., Miller J.Z., Weinberger M.H., et al. Genetic influences on the response to dietary salt reduction, acute salt loading, or salt depletion in humans. J Cardiovasc Pharmacol 1988, 12(Suppl 3):49-55.
30. Sallout B., Walker M. The fetal origin of adult diseases. J Obstet Gynaecol 2003, 23:555-560.
31. Keller G., Zimmer G., Mall G., et al. Nephron number in patients with primary hypertension. N Engl J Med 2003, 348:101-108.
32. Whelton P.K., He J., Cutler J.A., et al. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. JAMA 1997, 277:1624-1632.
33. Campese V.M. Calcium, parathyroid hormone, and blood pressure. Am J Hypertens 1989, 2:34S-44S.
34. Langford H.G. Dietary potassium and hypertension: epidemiologic data. Ann Intern Med 1985, 98:770.
35. Aviv A., Hollenberg N.K., Weder A. Urinary potassium excretion and sodium sensitivity in blacks. Hypertension 2004, 43:707-713.
36. Delgado M.C. Potassium in hypertension. Curr Hypertens Rep 2004, 6:31-35.
37. Hall J.E. The kidney, hypertension, and obesity. Hypertension 2003, 41:625-633.
38. Vasan R.S., Larson M.G., Leip E.P., et al. Assessment of frequency of progression to hypertension in nonhypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001, 358:1682-1686.
39. Egan B.M. Insulin resistance and the sympathetic nervous system. Curr Hypertens Rep 2003, 5:247-254.
40. Rahmouni K., Correia M.L., Haynes W.G., et al. Obesity-associated hypertension: new insights into mechanisms. Hypertension 2005, 45:9-14.
41. Goodfriend T.L., Calhoun D.A. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension 2004, 43:518-524.
42. Hall J.E., Hildebrandt D.A., Kuo J. Obesity hypertension: role of leptin and sympathetic nervous system. Am J Hypertens 2001, 14:103S-115S.
43. Lauer M.S., Okin P.M., Larson M.G., et al. Impaired heart rate response to graded exercise. Prognostic implications of chronotropic incompetence in the Framingham Heart Study. Circulation 1996, 93:1520-1526.
44. Juliti S., Schork M.A. Predictors of hypertension. Ann N Y Acad Sci 1978, 304:38-58.
45. Grassi G., Mancia G. Hyperadrenergic and labile hypertension. Comprehensive hypertension 2007, 719-726. Mosby Elsevier, Philadelphia. G.H. Lip, J. Hall (Eds.).
46. Muirhead E.E. Renal vasodepressor mechanisms: the medullipin system. J Hypertens 1993, 5:S53-S58.
47. Grassi G. Renin-angiotensin-sympathetic crosstalks in hypertension: reappraising the relevance of peripheral interactions. J Hypertens 2001, 19:1713-1716.
48. Grassi G., Cattaneo B.M., Seravalle G., et al. Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Circulation 1997, 96:1173-1179.
49. Grassi G., Quarti-Trevano F., Dell'Oro R., et al. Essential hypertension and the sympathetic nervous system. Neurol Sci 2008, 29. S33-6.
50. Erdos E.G. Angiotensin I converting enzyme and the changes in our concepts through the years. Lewis K. Dahl memorial lecture. Hypertension 1990, 16:363-370.
51. Chung O., Stoll M., Unger T. Physiologic and pharmacologic implications of AT1 versus AT2 receptors. Blood Press Suppl 1996, 2:47-52.
52. Zimmerman B.G., Sybertz E.J., Wong P.C. Interaction between sympathetic and renin-angiotensin system. J Hypertens 1984, 2:581-587.
53. Touyz R.M. The role of angiotensin II in regulating vascular structural and functional changes in hypertension. Curr Hypertens Rep 2003, 5:155-164.
54. Burns K.D., Li N. The role of angiotensin II-stimulated renal tubular transport in hypertension. Curr Hypertens Rep 2003, 5:165-171.
55. Kaschina E., Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press 2003, 12:70-88.
56. Dzau V.J. Theodore Cooper Lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001, 37:1047-1052.
57. Hannan R.E., Widdop R.E. Vascular angiotensin II actions mediated by angiotensin II type 2 receptors. Curr Hypertens Rep 2004, 6:117-123.
58. Widdop R.E., Jones E.S., Hannan R.E., et al. Angiotensin AT2 receptors: cardiovascular hope or hype?. Br J Pharmacol 2003, 140:809-824.
59. Carey R.M., Wang Z.Q., Siragy H.M. Update: role of the angiotensin type-2 (AT(2)) receptor in blood pressure regulation. Curr Hypertens Rep 2000, 2:198-201.
60. Julius S. Interaction between renin and the autonomic nervous system in hypertension. Am Heart J 1988, 116:611-616.
61. Weidmann P., De Myttenaere-Bursztein S., Maxwell M.H., et al. Effect on aging on plasma renin and aldosterone in normal man. Kidney Int 1975, 8:325-333.
62. Price D.A., Fisher N.D. The renin-angiotensin system in blacks: active, passive, or what?. Curr Hypertens Rep 2003, 5:225-230.
63. Sealey J.E., Blumenfeld J.D., Bell G.M., et al. On the renal basis for essential hypertension: nephron heterogeneity with discordant renin secretion and sodium excretion causing a hypertensive vasoconstriction-volume relationship. J Hypertens 1988, 6:763-777.
64. Tom B., Dendorfer A., Danser A.H. Bradykinin, angiotensin-(1-7), and ACE inhibitors: how do they interact?. Int J Biochem Cell Biol 2003, 35:792-801.
65. Folkow B. Physiological aspects of primary hypertension. Physiol Rev 1982, 62:347-504.
66. Berk B.C., Vekshtein V., Gordon H.M., et al. Angiotensin H-stimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension 1989, 13:305-314.
67. Naftilan A., Pratt R., Dzau V. Induction of c-fos, C-myc and PDGF A-chain gene expressions by angiotensin II in cultured vascular smooth muscle cells. J Clin Invest 1989, 83:1419-1424.
68. Gibbons G.H. Mechanisms of vascular remodeling in hypertension: role of autocrine-paracrine vasoactive factors. Curr Opin Nephrol Hypertens 1995, 4:189-196.
69. Pollman M.J., Yamada T., Horiuchi M., et al. Vasoactive substances regulate vascular smooth muscle cell apoptosis. Countervailing influences of nitric oxide and angiotensin II. Circ Res 1996, 79:748-756.
70. Dzau V.J. The role of mechanical and humoral factors in growth regulation of vascular smooth muscle and cardiac myocytes. Curr Opin Nephrol Hypertens 1993, 2:27-32.
71. Boden G., Shulman G.I. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002, 32(Suppl 3):14-23.
72. Pittas A.G., Joseph N.A., Greenberg A.S. Adipocytokines and insulin resistance. J Clin Endocrinol Metab 2004, 89:447-452.
73. Matsuzawa Y., Funahashi T., Kihara S., et al. Adiponectin and metabolic syndrome. Arterioscler Thromb 2004, 24:29-33.
74. Wheatcroft S.B., Williams I.L., Shah A.M., et al. Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet Med 2003, 20:255-268.
75. Dahl L.K., Heine M. Primary role of renal homo-grafts in setting chronic blood pressure levels in rats. Circ Res 1975, 36:692-696.
76. Lifton R.P. Molecular genetics of human blood pressure variation. Science 1996, 272:676-680.
77. Mackenzie H.S., Lawler E.V., Brenner B.M. Congenital oligo nephropathy: the fetal flaw in essential hypertension?. Kidney Int 1996, 55(Suppl):S30-S34.
78. Alam S., Johnson A.G. A meta-analysis of randomised controlled (trials (RCT)) among healthy normotensive and essential hypertensive elderly patients to determine the effect of high salt (NaCl) diet of blood pressure. J Hum Hypertens 1999, 13:367-374.
79. Midgley J.P., Matthew A.G., Greenwood C.M., et al. Effect of reduced dietary sodium on blood pressure: a meta-analysis of randomized controlled trials. JAMA 1996, 275:1590-1597.
80. Weinberger M.H., Fineberg N.S. Sodium and volume sensitivity of blood pressure age and pressure change over time. Hypertension 1991, 18:67-71.
81. Johnson R.J., Schreiner G.F. Hypothesis: the role of acquired tubulointerstitial disease in the pathogenesis of salt-dependent hypertension. Kidney Int 1997, 52:1169-1179.
82. Johnson R.J., Rodriguez-Iturbe B., Kang D.H., et al. A unifying pathway for essential hypertension. Am J Hypertens 2005, 18:431-440.
83. Julius S. The evidence for a pathophysiologic significance of sympathetic overactivity in hypertension. Clin Exp Hypertens 1996, 18:305-321.
84. Mancia G. Bjorn Folkow Award Lecture: the sympathetic nervous system in hypertension. J Hypertens 1997, 15:1553-1565.
85. Jeunemaitre X., Gimenez-Roqueplo A.P., Celerier J., et al. Angiotensinogen variants and human hypertension. Curr Hypertens Rep 1999, 1:31-41.
86. Johnson R.J., Titte S.R., Cade J.R., et al. Uric acid, evolution and primitive cultures. Semin Nephrol 2005, 25(1):3-8.
87. Johnson R.J., Rideout B.A. Uric acid and diet: insights into the epidemic of cardiovascular disease [editorial]. N Engl J Med 2004, 350:1071-1074.
88. Rodríguez-Iturbe B., Pons H., Quiroz Y., et al. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure. Kidney Int 2001, 59:2222-2232.
89. Williams G.H., Hollenberg N.K. Sodium-sensitive essential hypertension. Emerging insights into pathogenesis and therapeutic implications. Contemp Nephrol 1985, 3:303-311.
90. Lowenstein J., Beranbaum E.R., Chasis H., et al. Intrarenal pressure and exaggerated natriuresis in essential hypertension. Clin Sci 1970, 38:359-374.
91. Moritz A.R., Oldt M.R. Arteriolar sclerosis 111 hypertensive and non-hypertensive individuals. Am J Pathol 1937, 13:679-728.
92. Sánchez-Lozada L.G., Tapia E., Avila-Casado C., et al. Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol 2002, 283:F1105-F1110.
93. Sánchez-Lozada L.G., Tapia E., Santamaria J., et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 2005, 67(1):237-247.
94. Myers B.D., Deen W.M., Brenner B.M. Effects of norepinephrine and angiotensin II on the determinants of glomerular ultrafiltration and proximal tubule fluid reabsorption in the rat. Circ Res 1975, 25:663-673.
95. Bohle A., Ratschck M. The compensated and the decompensated form of benign nephrosclerosis. Pathol Res Pract 1982, 174:357-367.
96. Vaziri N.D. Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens 2004, 13:93-99.
97. Wilcox C.S. Redox regulation of the afferent arteriole and tubuloglomerular feedback. Acta Physiol Scand 2003, 179:217-223.
98. DiBona G.F. Sympathetic nervous system and the kidney in hypertension. Curr Opin Nephrol Hypertens 2002, 11:197-200.
99. Sommers S.C., Relman A.S., Smith wick R.H. Histologic studies of kidney biopsy specimens from patients with hypertension. Am J Pathol 1958, 34:715.
100. Egan B.M., Stepniakowski K.T. Adverse effects of short-term, very low-salt diets in subjects with risk-factor clustering. Am J Clin Nutr 1997, 65(Suppl 2):671S-677S.
101. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997, 57:2413-2416.
102. Chobanian A.V., Bakris G.L., Black H.R., et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003, 289(19):2560-2572.